– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad therapeutic areas, addressing large unmet medical needs April 25, 2024 -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely targets disease biology, today announced the publication of a new study in Science that validates the company’s foundational drug discovery app

Feb. 15, 2024 -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development. Taysha has been working to find ways to advance its deprioritized programs. On No

Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s disease Presented preclinical data supporting target identification and candidate differentiation across pipeline of antibody therapeutics at international neurology conferences ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerativ

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Both Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all hemophilia populations, presented at ASH 2021 Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran

The company recently announced that two wholly owned, precision oncology development candidates, EXS74539 ('539), an LSD1 inhibitor and EXS73565 ('565), a MALT1 protease inhibitor have been precision designed. Exscientia says this will improve the potential for patient benefit and solve complex design issues that could limit the probability of success of other compounds in the development. The company will provide an update on clinical development plans using its medicine platform during the s

In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV). Now real-world studies of patients treated outside of clinical trials confirm that long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver tests of these difficult-to-treat patients for the first time in 45 years, report investigators. In 2020,bulevirtide (BLV) was conditionall

Scientists have shed new light on aging processes in the brain. By linking the increased presence of specialized immune cells to conditions such as Alzheimer's disease and traumatic brain injury for the first time, they have unearthed a possible new target for therapies aimed at treating age-related neurological diseases. Scientists from the Trinity Biomedical Sciences Institute (TBSI) have shed new light on ageing processes in the brain. By linking the increased presence of specialised immune c

The California Department of Financial Protection and Innovation today closed Silicon Valley Bank, which could expose medtech companies with relations to the bank. The FDIC — appointed as receiver in the closing — created the Deposit Insurance National Bank of Santa Clara (DINB). This protects insured depositors, the FDIC said in a news release. At the time of closing, the FDIC immediately transferred to the DINB all insured deposits of Silicon Valley Bank. Silicon Valley Bank’s reach extends to

RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophrenia GRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical development COMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024 Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cas

The European Commission (EC) has granted AstraZeneca three new drug approvals, with the company’s Imfinzi/Imjudo immunotherapy combinations authorised for advanced liver and lung cancers, and a tablet formulation of Calquence for chronic lymphocytic leukaemia (CLL). The Imfinzi/ Imjudo approvals authorise the combination to be used for the first line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC), with the addition of platinum-based chemotherapy for adu